Oral Chemotherapeutic Silver Nanoparticles: Input of Drug Combinations
Cytotoxic drugs are used during cancer chemotherapy to inhibit tumor growth and metastasis. However, manychemotherapeutic drugs, such as doxorubicine (Dox), have limited cellular uptake and a strong tendency to bind to offtargetmacromolecules. Together these characteristics lead to low therapeutic indices. Increasing the intracellular uptake ofcancer drugs could prevent these complications.Another pitfall of chemotherapy is drug resistance. One strategy for avoiding drug resistance is drug combination. Thisapproach can prevent side effects by allowing for reduced dosages and can improve efficacy if the chosen drugs act synergistically.For example, bisphosphonates act synergistically with many other anti-cancer agents. Alendronate (Ald), one of the most potentbisphosphonates, has been shown to increase cancer cell death in vitro when combined with Dox in breast cancer cells.We present here the synthesis of a silver nanoparticle-based drug delivery system that improves the anticancer therapeuticindices of doxorubicin (Dox) using alendronate (Ald) as an adjuvent. Water, under microwave irradiation, was used as thesole reducing agent for the size-controlled, bisphosphonate-mediated preparation of silver nanoparticles (AgNPs). The AgNPswere coated with and stabilized by the bisphosphonate alendronate (Ald). The bisphosphonate group of Aldtemplated theformation of the AgNPs, and was the site of the drug’s attachment to the nanoparticles. The free primary ammonium group ofAld was subsequently functionalized with either Rhodamine B (RhB) by amide linker formation or Dox through imine bondformation. The RhB-conjugated nanoparticles (RhB-Ald@AgNPs) were studied in HeLa cell cultures. Confocal fluorescencemicroscopy studies determined the main mechanisms of cellular uptake of the nanoparticles. The imine linker of the Doxmodifiednanoparticles had significantly greater anti-cancer activity in vitro than either Ald or Dox alone.Thus, the ability of Ald to promote the assembly of Ald@AgNPs in a one step reaction, and the straightforward postmodificationof Ald@AgNPs, offer an easy and environmentally friendly strategy for the formation of stable nanoparticles thatcouple the antiproliferative properties of the AgNPs, themselves, to those of the drug mixtures they carry. This system featuresa high degree of functionality and potency and is of potential therapeutic benefit.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).